Centre François Baclesse

Centre François Baclesse is the Centre de Lutte Contre le Cancer for Caen and Lower Normandy, one of the 18 Unicancer centres. It provides surgery, medical oncology, radiotherapy and nuclear medicine, and is the clinical partner of the ARCHADE hadron therapy project, whose proton therapy centre in Caen treats patients from across the region. Research with the University of Caen Normandy and the GANIL heavy-ion laboratory covers radiobiology, radiotherapy physics, epidemiology and neuro-oncology. The centre is accredited by the Organisation of European Cancer Institutes as a Comprehensive Cancer Centre.

Location

Caen, FR

Type

cancer center

Website

www.baclesse.fr

Newsweek 2026 oncology rank

Not in top 300 listing used

OnCo score

#497 · 6 points (0 Newsweek + 0 NCI + 6 from 3 linked objects) · ranking

Research output

From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-24.

Matched to Centre François Baclesse, including child institutions. 278 works · 2,432 citations · 72% open access · 18% clinical trials · 0% reviews.

Oncology works per year

632022

622023

522024

612025

402026

Most works

Most cited

Work	Journal	Year	Citations
Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial 10.1038/s41591-023-02478-2 · open access	Nature Medicine	2023	392
Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology 10.1038/s12276-024-01272-5 · open access	Experimental & Molecular Medicine	2024	193
Abstract PD8-02: Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY) conference abstract · 10.1158/1538-7445.sabcs21-pd8-02	Cancer Research	2022	108
Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). conference abstract · 10.1200/jco.2024.42.17_suppl.lba1000	Journal of Clinical Oncology	2024	107
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial 10.1200/jco.21.02937 · open access	Journal of Clinical Oncology	2022	84
Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy 10.1200/jco.21.00277 · open access	Journal of Clinical Oncology	2022	77
Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care 10.1200/jco.21.01252 · open access	Journal of Clinical Oncology	2022	63
Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer 10.1038/s41416-024-02766-9 · open access	British Journal of Cancer	2024	57
Radioresistance of Non-Small Cell Lung Cancers and Therapeutic Perspectives 10.3390/cancers14122829 · open access	Cancers	2022	49
Characterization of Depressive Symptoms Trajectories After Breast Cancer Diagnosis in Women in France 10.1001/jamanetworkopen.2022.5118 · open access	JAMA Network Open	2022	49
LBA1 Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): Biomarker analyses from patients from DAISY trial 10.1016/j.annonc.2022.03.277 · open access	Annals of Oncology	2022	48
Randomized phase III study of nivolumab and ipilimumab versus carboplatin-based doublet in first-line treatment of PS 2 or elderly (≥ 70 years) patients with advanced non–small cell lung cancer (Energy-GFPC 06-2015 study). conference abstract · 10.1200/jco.2022.40.16_suppl.9011	Journal of Clinical Oncology	2022	35
Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer 10.1158/1078-0432.ccr-23-0898 · open access	Clinical Cancer Research	2023	28
Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma 10.1186/s13046-023-02809-8 · open access	Journal of Experimental & Clinical Cancer Research	2023	27
Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study 10.1016/j.lungcan.2023.107379 · open access	Lung Cancer	2023	27

Programmes

3top

Proton therapy (ARCHADE)
Radiobiology
Radiotherapy

People

1top

Roman Rouzier

Directeur Général (Director General), Centre François Baclesse

Gynaecological surgeryBreast surgeryCancer centre management

Gynaecological and breast surgeon who has directed Centre François Baclesse, the comprehensive cancer centre for Normandy in Caen, since July 2023.

Connected

4top

Institution
Institut du Cancer de Montpellier (ICM)
Shares UNICANCER, Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre, unicancer.
Institution
Centre Jean Perrin
Shares UNICANCER, Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre, unicancer.
Institution
Centre Henri Becquerel
Shares UNICANCER, Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre, unicancer.
Institution
Centre Eugène Marquis
Shares UNICANCER, Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre, unicancer.
Institution
Institut de Cancérologie de l'Ouest (ICO)
Shares UNICANCER, Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre, unicancer.
Institution
University Medical Center Groningen Comprehensive Cancer Center
Shares Proton therapy, Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre.
Institution
Maastricht UMC+ Comprehensive Cancer Center
Shares Proton therapy, Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre.
Institution
Hospital Universitario Fundación Jiménez Díaz
Shares Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre.

Research output

Programmes

People

Connected

Similar pages

technologies

companies

institutions

people

Centre François Baclesse

Research output

Programmes

People

Connected

Similar pages

technologies

companies

institutions

people

Centre François Baclesse

Overview

Research output

Programmes

People

Connected

Similar pages

technologies

companies

institutions

people

Centre François Baclesse

Overview

Research output

Programmes

People

Connected

Similar pages

technologies

companies

institutions

people